|
谷小珂，教授，博士，硕士生导师 |
科学研究方向 |
|
抗肿瘤及糖尿病并发症药物分子的设计、合成及生物活性研究 |
|
联系方式 |
|
电 话：0516-83262137 |
|
Email：gu_xk@xzhmu.edu.cn |
|
通 讯：江苏省徐州市云龙区铜山路209号，221004 |
个人简历
江苏省“六大人才高峰”和“333高层次人才培养工程”培养对象。2012年毕业于中国药科大学药物化学专业，获理学博士学位，同年进入威廉公司官网任职。2020年于美国明尼苏达大学交流访学一年。近年来研究方向为抗肿瘤及糖尿病并发症药物分子的设计、合成及生物活性研究，先后主持国家自然科学基金青年项目、江苏省自然科学基金面上项目、江苏省肿瘤生物治疗重点实验室开放课题、徐州市自然科学基金、williamhill登录入口优秀人才科研启动基金、威廉公司官网经理人才专项等。以第一或通讯作者在Journal of Medicinal Chemistry、European Journal of Medicinal Chemistry、Bioorganic & Medicinal Chemistry、Bioorganic & Medicinal Chemistry Letters等药物化学权威杂志发表SCI论文20余篇，申请专利6项（已授权4项，转让1项）。作为合成项目负责人，完成企业横向课题2项。教学方面主要承担研究生《化员工物学进展》以及药学、临床药学、药物制剂等本科专业的《药物化学》、《药物设计》、《有机化学》等课程的理论及实验教学。先后获得全国高等学校药学类专业青年教师微课教学大赛二等奖、江苏省高校微课教学比赛三等奖、williamhill登录入口青年教师讲课考核比赛优秀奖、威廉公司官网青年教师讲课比赛一等奖等。
承担科研课题
1. 江苏省自然科学基金面上项目，BK20211056，基于光药理学的新型P-gp抑制剂的设计、合成及逆转肿瘤MDR活性研究，2021.07-2024.06，10万元，主持；
2. 江苏省第五期“333高层次人才培养工程”科研资助项目，BRA201927，具有抗肿瘤MDR活性的NO供体型HDACs抑制剂的设计、合成及作用机制研究，2019.09-2021.09，12万元，主持；
3. 江苏省“六大人才高峰”高层次人才项目，YY-039，基于NO和附属敏感性的新型HDACs抑制剂的设计、合成及抗肿瘤MDR活性研究，2018.01-2020.12，8万元，主持
4. 国家自然科学基金青年基金，81402789，具有多重作用机制的新型肿瘤MDR逆转剂的设计、合成及其活性研究，2015.01-2017.12，23万元，主持；
5. 江苏省自然科学基金面上项目，BK20171179，具有抗肿瘤MDR活性的NO供体型HDACs抑制剂的设计、合成及作用机制研究，2017.07-2020.06，10万，主持；
6. 徐州市科技计划项目，KC16SG254，基于迈克尔受体的Nrf2激活剂的设计、合成及抗DN活性研究，2016.07-2018.06，5万，主持；
7. 徐州医学院优秀人才科研启动基金，新型肿瘤多药耐药逆转剂的设计、合成及其活性研究，2013.06-2016.06，30万，主持。
近五年代表性论文、专著
1. Xiaoke Gu, Haoxing Yuan, Wenchao Zhao, Nan Sun, Wenzhong Yan, Chunyu Jiang, Yan He, Hongli Liu, Jianjun Cheng, Dong Guo, Optical-controlled kinetic switch: fine-tuning of the residence time of an antagonist binding to the vasopressin V2 receptor in in vitro, ex vivo, and in vivo models of ADPKD, Journal of Medicinal Chemistry, 2023, 66, 1454−1466.
2. Chunyu Jiang, Ting Pan, Yunxiang Jiang, Zhiyu Zhang, Meifeng Zeng, Shuang Sun, Zheng Li, Yiqing Wu, Jingying Qiu, Mingshan Niu , Xiaoke Gu (通讯作者), Design and evaluation of dibenzoazepine-tetrahydroisoquinoline hybrids as potential P-glycoprotein inhibitors against multidrug resistant K562/A02 cells, European Journal of Medicinal Chemistry, 2023, 249, 115150.
3. Jingying Qiu, Yueting Zou, Shuqiong Li, Lihua Yang, Zibin Qiu, Fanyun Kong, Xiaoke Gu (通讯作者), Discovery of benzimidazole substituted 1, 2, 4-oxadiazole compounds as novel anti-HBV agents with TLR8-agonistic activities, European Journal of Medicinal Chemistry, 2022, 244, 114833.
4. Jingying Qiu, Qingqing Zhou,Yueting Zou, Shuqiong Li, Lihua Yang, Wang Chen, Jian Gao, Xiaoke Gu (通讯作者), Design and synthesis of novel quinazolinone derivatives as anti-HBV agents with TLR8 agonist effect, European Journal of Medicinal Chemistry, 2022, 231, 114159.
5. Jingying Qiu, Yueting Zou, Qingchuan Liu, Chunyu Jiang, Qingqing Zhou, Shuqiong Li, Wang Chen, Zheng Li, Xiaoke Gu (通讯作者), Synthesis and evaluation of novel quinazolinone derivatives as potential anti-HCC agents, Chemistry & Biodiversity, 2022, 19(2): e202100766.
6. Xiaoke Gu, Yinpeng Zhang, Yueting Zou, Xin Li, Mingyu Guan, Qingqing Zhou, Jingying Qiu, Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents, Bioorganic & Medicinal Chemistry, 2021, 29:115892.
7. Xiaoke Gu, Mingyu Guan, Chunyu Jiang, Qinghua Song, Xin Li, Nan Sun, Jing Chen, Jingying Qiu. Assessment of Thiosemicarbazone-Containing Compounds as Potential Antileukemia Agents against P-gp Overexpressing Drug Resistant K562/A02 Cells, Chemistry & Biodiversity, 2021, 18(2).
8. Jingying Qiu, Qingqing Zhou, Yinpeng Zhang, Mingyu Guan, Xin Li, Yueting Zou, Xuan Huang, Yali Zhao, Wang Chen, Xiaoke Gu (通讯作者), Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents, European Journal of Medicinal Chemistry, 2020, 205:112581.
9. Xiaoke Gu, Xin Li, Mingyu Guan, Chunyu Jiang, Qinghua Song, Nan Sun, Yueting Zou, Qingqing Zhou, Jing Chen, Jingying Qiu, Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells, Bioorganic & Medicinal Chemistry Letters, 2020, 30(24): 127638.
10.Xiaoke Gu, Jing Chen, Yinpeng Zhang, Mingyu Guan, Xin Li, Qingqing Zhou, Qinghua Song, Jingying Qiu, Synthesis and assessment of phenylacrylamide derivatives as potential anti-oxidant and anti-inflammatory agents, European Journal Of Medicinal Chemistry, 2019, 180: 62-71.
11.Xiaoke Gu, Yanfei Jiang, Jing Chen, Yinpeng Zhang, Mingyu Guan, Xin Li, Qingqing Zhou, Qian Lu, Jingying Qiu, Xiaoxing Yin, Synthesis and biological evaluation of bifendate derivatives bearing acrylamide moiety as novel antioxidant agents, European Journal Of Medicinal Chemistry, 2019, 162: 59-69.
12.Xiaoke Gu, Yanfei Jiang, Yingying Qu, Jing Chen, Dingding Feng, Chenglin Li, Xiaoxing Yin, Synthesis and biological evaluation of bifendate derivatives bearing 6,7-dihydro-dibenzo c,e azepine scaffold as potential P-glycoprotein and tumor metastasis inhibitors, European Journal of Medicinal Chemistry, 2018, 145: 379-388.
13.Jingying Qiu, Qineng Gong, Jian Gao, Wang Chen, Yinpeng Zhang, Xiaoke Gu (共同通讯), Daoquan Tang, Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors, European Journal of Medicinal Chemistry, 2018, 144: 424-434.
14.Jingying Qiu, Wang Chen, Yanfei Jiang, Jing Chen, Yinpeng Zhang, Xiaoke Gu (通讯作者), Assessment of a bifendate derivative bearing a 6,7-dihydro-dibenzo[c,e]azepine scaffold as a potential anti-metastatic agent, Medchemcomm, 2018, 9 (11): 1826-1830.
15.Xiaoke Gu, Zhangjian Huang, Zhiguang Ren, Xiaobo Tang, Rongfang Xue, Xiaojun Luo, Sixun Peng, Hui Peng, Bin Lu, Jide Tian, Yihua Zhang, Potent Inhibition of Nitric Oxide-Releasing Bifendate Derivatives against Drug-Resistant K562/A02 Cells in Vitro and in Vivo, Journal of Medicinal Chemistry, 2017, 60 (3): 928-940.
